Blue Therapeutics has released the second part of a receptor-interactomics™ concept paper series, “Innate Proximity: inherent physicality of receptor interactions” by Ajay Yekkirala, CSO and co-founder of Blue Therapeutics.
As part of Blue’s strategic expansion and ongoing fundraising activities, the company is sharing insights into the exciting world of receptor interactions and why they have to be considered drug targets in their own right. The paper also sheds light on how they ultimately create benefits for patients across a variety of indications with high unmet need.
Docbot, Inc., an artificial intelligence (AI) technology company focusing on gastrointestinal (GI) disease, announced today the closing of a Series A round. In conjunction with the financing, the company has appointed Andrew J. Ritter as CEO after he led the sale of Ritter Pharmaceuticals (NASDAQ:RTTR) in 2020.
Andrew earned an MBA from the Wharton School at the University of Pennsylvania and has over 16 years’ experience in GI disease.
Docbot’s founding CEO, Andrew Ninh, continues as Chief Strategic Officer and will lead business development, strategic partnerships and innovation.
The company recently closed a $4 million Series A led by Khosla Ventures, with participation by Bold Capital Partners, Collaborative Fund and Boutique Venture Partners, bringing the total amount raised to $8.5 million since inception.
Docbot’s investigational device, UltivisionAI, uses artificial intelligence for automated GI disease detection. The new capital will be used to advance clinical trials and seek FDA clearance. To read more, click here.
Central Florida Health System AdventHealth and Sema4, a patient-centered health intelligence company using AI to derive data-driven insights, are collaborating in a move that builds upon the current AdventHealth Genomics and Personalized Health Program to provide new research insights and to prevent, detect and treat disease in their patients.
“AdventHealth views genomics and personalized medicine as critical to the future of wellness and health care, and we are delighted to collaborate with Sema4 on this important journey,” said Dr. Steven Smith, chief scientific officer for AdventHealth. “This technology and collaboration will allow us to interpret vast amounts of clinical, genomic and other patient data to discover and provide lifesaving treatments to patients who previously would not have had those options.” To read more, click here.
New Mexico Cancer Center has announced a strategic partnership with Deep Lens, a biotech company that applies AI to clinical trial recruitment. NMCC will integrate AI-based clinical trial screening and enrollment solution, VIPER™, into the NMCC network.
VIPER uses proprietary, cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process. Through this collaboration, NMCC will be able to more effectively identify, screen and match oncology patients to precision-based clinical trials. To read more, click here.
Picture: akindo, Getty Images
